![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ICER Finds Treatments for Cardiovascular Disease Cost-Effective
ICER Finds Treatments for Cardiovascular Disease Cost-Effective
October 30, 2019
In its latest cost-benefit analysis, the Institute for Clinical and Economic Review (ICER) found that Janssen’s Xarelto (rivaroxaban) and Amarin Pharma’s Vascepa (icosapent ethyl) are cost-effective treatments for cardiovascular disease — provided not all eligible patients are treated.
The non-profit drug price watchdog found that along with providing a substantial clinical benefit, both drugs fell within its thresholds for cost-effectiveness.
In terms of clinical evidence, ICER found that in combination with aspirin, Xarelto reduced the risk of cardiovascular death, stroke or heart attack in patients with stable cardiovascular disease. Vascepa in combination with aspirin or other statins reduced the same risks, as well as the risk of bypass surgery or other procedures in patients with the disease.
Upcoming Events
-
21Oct